Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA7 | P43166 | 5/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536325 | 0.90 | CA1 (0.44) | CA1CA2ROCK1LIPGLPL | |
| SCHEMBL20722767 | 0.84 | MTNR1A (0.43) | LMNAROCK1HIF1A | |
| SCHEMBL20722763 | 0.84 | MTNR1A (0.43) | LMNAROCK1HIF1A | |
| SCHEMBL29991805 | 0.84 | PRMT5 (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL15100254 | 0.84 | PRMT5 (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL21557501 | 0.82 | KMT2A (0.39) | CA1CA2CA12CA7CA14 | |
| SCHEMBL23364981 | 0.79 | ROCK1 (0.40) | CA1CA2CA12CA7CA14 | |
| SCHEMBL23364978 | 0.79 | ROCK1 (0.40) | CA1CA2CA12CA7CA14 | |
| SCHEMBL16100403 | 0.79 | LIPG (0.41) | CA1CA2CA12CA7CA14 | |
| SCHEMBL15096664 | 0.77 | LIPG (0.42) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9469617-B2 | Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto | DOW AGROSCIENCES LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20160060233-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CA1 3966/4885CA2 257/4885CA12 4676/4885 |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CA1 3906/4885CA2 4247/4885CA12 4400/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CA1 3966/4885CA2 257/4885CA12 4676/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CA1 3966/4885CA2 257/4885CA12 4676/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | CA1 4029/4885CA2 2823/4885CA12 4245/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CA1 3966/4885CA2 257/4885CA12 4676/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CA1 3906/4885CA2 4247/4885CA12 4400/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | CA1 4026/4885CA2 4674/4885CA12 3741/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CA1 3966/4885CA2 257/4885CA12 4676/4885 |
| US-20160060233-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | CA1 2314/4885CA2 377/4885CA12 3156/4885 |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, GAA | CA1 1590/4885CA2 891/4885CA12 969/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | CA1 4029/4885CA2 2823/4885CA12 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.